Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development

Project Originated at Rockefeller University and Graduated From Tri-Institutional Therapeutics Discovery Institute

NEW YORK, March 14, 2018 – PRNewswire

Bridge Medicines and the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) announced today the acceptance into Bridge Medicines of its first drug candidate, a small molecule for the treatment of basal cell carcinoma, that originated in the laboratory of Rockefeller University’s Dr. Tarun Kapoor and successfully completed pre-clinical trials at Tri-I TDI.